EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Longitudinal Evaluation of an Abbreviated Patient‐Reported Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale ( MDS ‐ UPDRS) for Predicting Dopaminergic Therapy Initiation in Early Parkinson's Disease

Mohammad Samsul Alam iD, Luowen Yu, Glenn T Stebbins, Tiago A Mestre iD, Christopher G Goetz, Sheng Luo iD

Movement Disorders · 2026

DOI: 10.1002/mds.70096 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Movement Disorders, 2026. Verfasst von Mohammad Samsul Alam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics & Bioinformatics, Duke University, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Parkinson Disease, Severity of Illness Index, Dopamine Agents, Antiparkinson Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, International Parkinson and Movement Disorder Society, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Predicting initiation of dopaminergic therapy in early Parkinson's disease ( PD ) is important for clinical management and trial design. Prior cross‐sectional work identified a six‐item patient‐reported subset from the Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale ( MDS ‐ UPDRS) Parts IB + II , but its longitudinal utility is unknown.

Objectives

To test whether modeling longitudinal symptom trajectories improves prediction of dopaminergic therapy initiation beyond baseline‐only models, and to identify an abbreviated patient‐reported subset with stable prognostic value and utility for trial stratification.

Methods

Data were harmonized from 1787 untreated early PD patients across six multicenter studies. All 20 MDS ‐ UPDRS Parts IB + II items were analyzed using a longitudinal item response theory model. Items were ranked by discrimination and information functions, and cumulative subsets evaluated in Cox models with time‐dependent covariates, adjusted for age, sex, disease duration, and Hoehn and Yahr stage. Predictive accuracy was quantified by concordance index (C‐index) for full follow‐up and truncation at 1 and 2 years. Risk stratification was assessed based on baseline abbreviated subset scores using Kaplan–Meier analyses.

Results

An 11‐item model consistently outperformed the full 20‐item scale (C‐index 0.609 vs. 0.597, P < 0.001 with full follow‐up; 0.621 vs. 0.599, P < 0.001 at 1 year; 0.615 vs. 0.602, P < 0.001 at 2 years). Longitudinal updates improved discrimination over baseline‐only models (eg, 0.609 vs. 0.594 for full follow‐up). Higher baseline 11‐item scores were strongly associated with earlier therapy initiation.

Conclusions

Longitudinal symptom modeling improves prediction of therapy initiation in early PD . An abbreviated 11‐item patient‐reported MDS ‐ UPDRS provides stronger prognostic value than the full scale and supports trial stratification and clinical monitoring. © 2025 International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseSeverity of Illness IndexDopamine AgentsAntiparkinson AgentsHumansMaleFemaleMiddle AgedAgedLongitudinal StudiesPatient Reported Outcome Measures

Stichwörter der Autor:innen

Parkinson's progressionclinical predictionpatient‐reported outcomes

Substanzen

Dopamine AgentsAntiparkinson Agents

Autor:innen und Institutionen

  • Department of Biostatistics & Bioinformatics, Duke University, Durham, North Carolina, USA.
  • Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.
  • Division of Neurology, Department of Medicine, Ottawa Hospital Research Institute University of Ottawa Brain and Mind Research Institute, University of Ottawa, The Ottawa Hospital, Ottawa, Ontario, Canada.

ORCID-Profile: Mohammad Samsul Alam, Tiago A Mestre, Sheng Luo

Förderung

  • NIA NIH HHS
  • International Parkinson and Movement Disorder Society
  • National Institute on Aging

Zitieren

APA

Alam, M. S., Yu, L., Stebbins, G. T., Mestre, T. A., Goetz, C. G., & Luo, S. (2026). Longitudinal Evaluation of an Abbreviated Patient‐Reported Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale ( MDS ‐ UPDRS) for Predicting Dopaminergic Therapy Initiation in Early Parkinson's Disease. Movement Disorders. https://doi.org/10.1002/mds.70096

Vancouver

Alam MS, Yu L, Stebbins GT, Mestre TA, Goetz CG, Luo S. Longitudinal Evaluation of an Abbreviated Patient‐Reported Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale ( MDS ‐ UPDRS) for Predicting Dopaminergic Therapy Initiation in Early Parkinson's Disease. Movement Disorders. 2026. doi:10.1002/mds.70096

BibTeX
@article{Alam2026,
  author = {Alam, Mohammad Samsul and Yu, Luowen and Stebbins, Glenn T and Mestre, Tiago A and Goetz, Christopher G and Luo, Sheng},
  title = {Longitudinal Evaluation of an Abbreviated Patient‐Reported Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale ( MDS ‐ UPDRS) for Predicting Dopaminergic Therapy Initiation in Early Parkinson's Disease},
  journal = {Movement Disorders},
  year = {2026},
  doi = {10.1002/mds.70096}
}
Kostenlos starten →